Opendata, web and dolomites

Tuberculini SIGNED

A novel in-vitro diagnostic test for drug-resistant tuberculosis and a personalized antibiotic treatment plan.

Total Cost €


EC-Contrib. €






 Tuberculini project word cloud

Explore the words cloud of the Tuberculini project. It provides you a very rough idea of what is the project "Tuberculini" about.

opportunity    73    financial    swiss    p1    resistant    detect    ivds    diagnosed    becton    total    causes    antimicrobial    data    significantly    addressable    algorithms    learning    matching    dickinson    contributor    tuberculosis    market    vs    commercial    sequencing    patient    lifescience    tests    uses    mdr    business    samples    advantage    minimum    12    feasibility    inability    prescription    vision    ag    susceptibility    primers    cepheid    battle    annotate    detection    240k    platform    founded    off    ivd    profiles    clemedi    drug    antibiotics    company    university    machine    world    person    infections    tuberculini    diseases    spin    proprietary    vitro    diagnostic    hain    10k    resistance    caused    mortalities    solution    zurich    infectious    competitive    companies    valued    amplify    generation    dna    ngs    diagnose    death    plan    smei    tb    disease    personalized    rapid    therapy    2019    larger    global    sme    advice    2050    24    antibiotic    competitors    hours    followed    obtaining    48    analyze    positively   

Project "Tuberculini" data sheet

The following table provides information about the project.


Organization address
address: WAGISTRASSE 12
postcode: CH-8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CLEMEDI AG CH (SCHLIEREN) coordinator 50˙000.00


 Project objective

Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.

Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.

Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.

Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.

Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUBERCULINI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUBERCULINI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

LTS (2020)


Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More